The 2025 annual meeting of the Association for Molecular Pathology (AMP) wrapped up over the weekend. From November 11 through November 15, the 2025 AMP Annual Meeting & Expo featured five days of expert-led discussions, insightful research presentations, and excellent networking opportunities in Boston, Massachusetts.

Out of the hundreds of abstracts published, we curated a list of selected oncology research topics and their associated descriptions and conclusions, for your convenience. Some of the following descriptions and conclusions have been edited for brevity and clarity. For a complete look at all of the abstracts published for the 2025 AMP Annual Meeting & Expo, visit the Journal of Molecular Diagnostics website where you can download a .pdf file that includes every abstract.

Impact of Reclassification and Subcategorization of Variants of Uncertain Significance in Acute Myeloid Leukemia

  • Description: Reclassification rates of variants of uncertain significance are not known in acute myeloid leukemia. Overall, there is a lack of information on when and how to reclassify VUSs in  somatic cancers, including acute myeloid leukemia. [Researchers] reclassified variants of uncertain significance to determine overall reclassification rates. Furthermore, variants of uncertain significance were subcategorized to determine how often to perform variant reviews, how to track variant evidence, and how to incorporate variants of uncertain significance subcategories into clinical reporting.
  • Conclusion: A reclassification rate of 12.8% was observed in acute myeloid leukemia. Variants of uncertain significance subcategories may help to prioritize variants of unknown significance for review, reduce overall review time, and may help in reporting variants that are associated with drug response in acute myeloid leukemia but do not have enough evidence based on oncogenicity assessment.

Comprehensive Validation of Duoseq, a Novel Assay for Simultaneous DNA and RNA Sequencing in Hematolymphoid Malignancies

  • Description: Duoseq was developed as a streamlined next-generation sequencing solution that processes DNA and RNA simultaneously in a single workflow, detecting mutations, structural variants, fusions, and clonotypes.
  • Conclusion: The study found Duoseq to be reliable and cost-effective, providing a streamlined workflow for testing a wide range of hematolymphoid malignancies.

Analytical and Clinical Evaluation of the Alinity m EBV Assay for Quantification of EBV DNA in Plasma Specimens from Patients with Nasopharyngeal Carcinoma

  • Description: This study evaluated the analytical and clinical performance of the Alinity m EBV assay and compared it to a validated laboratory-developed test used in nasopharyngeal carcinoma patient management.
  • Conclusion: The Alinity m EBV assay demonstrated a linearity of 1 using the verification panel and a total standard deviation of ≤0.06 log IU/mL. The Alinity m EBV assay demonstrated comparable results with the laboratory-developed test with a correlation of 0.95 and overall percent agreement of 92.8%. Overall, Alinity m EBV assay bias was lower than the laboratory-developed test assay (0.43 log IU/mL).

Validation of Custom Digital Droplet PCR Assay for Identification of POLE-Gene Mutations for Endometrial Cancer Prognostication

  • Description: [Researchers presented their] clinical validation of a custom droplet digital polymerase chain reaction assay that evaluates 16 POLE mutations associated with endometrial cancer hypermutator phenotype.
  • Conclusion: We validated a cost-effective POLE ddPCR assay for formalin-fixed, paraffin-embedded samples with low tumor purity (limit of detection <1%) with a rapid turn-around time. This targeted ddPCR assay is especially advantageous for early-stage endometrial cancers that do not require comprehensive genomic profiling but do require molecular subgrouping as part of routine histopathologic diagnosis.

Artificial Intelligence-Powered Spatial Analysis Reveals Distinct Tumor-Immune Microenvironments Associated with MET Mutations in Non-Small Cell Lung Cancer

  • Description: This study aimed to leverage artificial intelligence (AI)-powered spatial analysis of WSIs to characterize the immune phenotypes and cellular composition associated with different MET mutation status in NSCLC.
  • Conclusion: We detected distinct TMEs associated with different MET alterations in NSCLC. MET exon 14 skipping-mutated tumors display an "inflamed" or "hot" phenotype, indicating a more heterogeneous and potentially immunotherapy-responsive TME. Conversely, MET-amplified tumors exhibit characteristics of an "immune- desert" or "cold" TME, suggesting potential resistance to immunotherapy.

Rapid, Cost-Effective TempO-Seq Profiling Outperforms Oncotype DX for Risk Stratification in Early-Stage Breast Cancer

  • Description: [Researchers] designed a TempO-Seq panel that contained probes targeting the 21 genes of the Oncotype DX signature. Data from pilot experiments pinpointed transcripts with high or low expression. For the final panel, high expressor signals were attenuated, whereas low-expressed genes underwent probe over-design by incorporating supplementary probes. Sample processing and reaction conditions were optimized to deliver robust data from a single 5 µm-thick, 1 mm-diameter TMA core. The optimised panel and workflow were applied to [the researchers’] study cohort, comprising 245 breast cancer tumours with matched Oncotype DX scores and recurrency data. Using the expression data, we trained a support vector machine to replicate Oncotype DX classifications and tested other machine learning algorithms to directly predict actual 10-year recurrence status.
  • Conclusion: TempO-Seq enables accurate, reproducible recurrence prediction from minimal input in 2 days. Its performance surpasses Oncotype DX, offering a cost-effective, clinically viable alternative for risk stratification in early-stage HR+/HER2- breast cancer.

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, all rights reserved.